ČESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2019

346 KAZUISTIKY Ces Urol 2019; 23(4): 341–346 Na prezentované kazuistice vidíme zajímavou kompletní radiologickou regresi plicního nálezu po léčbě sunitibem v první linii, další zajímavostí jsou výrazné regresivní změny v primárnímnádoru ledviny po cílené léčbě. Parciální remise onemocnění trvala sedmměsíců. ZÁVĚR I přes moderní cílenou léčbu, která vede u řady pacientů k remisi onemocnění, je mRCC závažné nevyléčitelné onemocnění. Cílená léčba pacientů výrazně prodlouží život se zachováním jeho kvality. LITERATURA: 1. Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary non‑metastatic patients: a population‑based study. World J Urol 2016 ; 34(8) : 1081–1086. 2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon‑alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002 ; 20(1) : 289–296. 3. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high‑dose recombinant interleukin-2 therapy. J Clin Oncol 1995 ; 13(3) : 688–696. 4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear‑cell renal‑cell carcinoma. N Engl J Med 2007 ; 356(2) : 125–134. 5. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama 2006 ; 295(21) : 2516–2524. 6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 ; 27(22) : 3584–3590. 7. Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First‑line Treatment of Metastatic Clear‑cell Renal Cell Carcinoma. Eur Urol 2019 ; 76(2): 151–156. 8. Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian Journal of Urology 2016 ; 3(4): 286–292. 9. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016 ; 35(21): 2687–2697. 10. Callea M, Albiges L, Gupta M, et al. Differential Expression of PD‑L1 between Primary and Metastatic Sites in Clear‑Cell Renal Cell Carcinoma. Cancer Immunol Res 2015 ; 3(10): 1158–1164. 11. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 ; 24(1): 25–35. 12. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014 ; 50(6): 1084–1089. 13. Staehler M, Haseke N, Zilinberg E, et al. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 2010 ; 28(2): 139–144. 14. Mejean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal‑Cell Carcinoma. N Engl J Med 2018 ; 379(5): 417–427. 15. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Rando‑ mized Clinical Trial. JAMA Oncol 2019 ; 5(2): 164–170. 16. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014 ; 15(12): e549–561.